Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BiondVax Moves to New Flu Vaccine Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

BiondVax Moves to New Flu Vaccine Mfg. Facility

State-of-the-art facility designed for annual capacity of 40 million doses in bulk with up to 20 million single dose syringes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BiondVax Pharmaceuticals, developer of the M-001 universal influenza vaccine candidate, has relocated to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel.

“BiondVax’s new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza,” said Shimon Hassin, chief operating officer, BiondVax. “As BiondVax moves into this next exciting stage, I would like to thank our partners at Biopharmax for the design and construction of our new facility.”

Based in the Jerusalem Bio Park, a biotech hub on the Hadassah Medical Center Hebrew University Ein Kerem campus, the new approximately 20,000 square foot facility includes offices, laboratories, and GMP manufacturing suites with potential annual capacity of 40 million doses of M-001 in bulk with up to 20 million single dose syringes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics